Cholongitas E, Goulis I, Pagourelias E, Birtsou C, Ioannidou M, Chalevas P, Soulaidopoulos S, Vassilikos V, Akriviadis E

Language: English
References: 24
Page: 745-751
PDF size: 155.77 Kb.

ABSTRACT

Background/Aim. The pathogenesis and the clinical impact of diastolic dysfunction (DD) in cirrhosis remain unclear. Our aim was to investigate the factors significantly associated with the presence of DD in patients with decompensated cirrhosis on the waiting list for liver transplantation. Material and methods. consecutive patients with decompensated cirrhosis, who admitted for transplant assessment, were prospectively evaluated. We assessed the independent factors associated with the presence of DD, while their discriminative ability was evaluated by AUC curve. The diagnosis of DD was based on Doppler echocardiography and classified into three categories according to the current guidelines. Results. we evaluated 115 consecutive patients. Sixty six patients (57.3%-group 1) had DD and 49 (42.7%-group 2) had not DD. The 2 groups had similar Child-Pugh/MELD scores and survival. In multivariable logistic regression analysis, pulse rate (OR: 1.082, 95% CI: 1.03-1.15, p = 0.004), and UNa24h (OR: 0.98, 95% CI: 0.97- 0.99, p = 0.004) were the only variables independently associated with the presence of DD. In the subgroup of consecutive patients (n = 31) with evaluation of cytokines, those (n = 22) with DD, compared to those (n = 9) without DD, had significantly higher levels of inteleukin-6 [145 (45-2000) vs. 56 (10-149)pg/mL, p = 0.043]. Conclusions. We found that DD was independently associated with lower 24-hour urine sodium. Although no correlation was found between DD and severity of liver disease or survival, further studies are needed for final conclusions.

REFERENCES

1. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-90.

2. Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent Advances in Cirrhotic Cardiomyopathy. Dig Dis Sci 2015; 60: 1141-51.

3. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol 2015; 28: 31-40.

4. Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 125-40.

5. Cholongitas E, Goulis J, Arsos G, Birtsou C, Nakouti T, Papadopoulou S, Chalevas P, et al. Association between ratio of sodium to potassium in random urine samples and renal dysfunction and mortality in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 862-7.

6. Pugh R, Murray-lyon I, Dawson J. Transcection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

7. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.

8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.

9. Fleming JS, Nunan TO. The new BNMS guidelines for measurement of glomerular filtration rate. Nucl Med Commun 2004; 25: 755-7.

10. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function—a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-66.

11. Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, Vilstrup H. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011; 31: 534-40.

12. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.

13. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294- 304.

14. Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 2014; 8: 308-15.

15. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, De CS, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97: 142-8.

16. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, Afeltra A, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56: 539-49.

17. Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, Pectasides D. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 2012; 25: 1174-81.

18. 18 Pozzi M, Carugo S, Boari G, Pecci V, De CS, Maggiolini S, Bolla GB, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-7.

19. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97: 259-67.

20. Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, Arroyo V, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013; 58: 51-7

21. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.

22. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014; 61: 1385-96.

23. Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis- Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci 2013; 58: 3029-36.

24. Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, Gaudio C, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 2013; 24: 172-6.